Skip to content

Susan B Powell

12 papers in the library · 293 citations · publishing 2009-2026

Papers

Sort Most recent Most cited

Investigation of the pharmacological and circuit basis for psychedelic drug effects on interval timing in mice.

Psychopharmacology October 19, 2026 Landon M. Klein, Jared M. Kopelman, Richard F Sharp et al.

Classical psychedelic drugs such as the tryptamine psilocybin can alter temporal perception. Previously, the phenylethylamine psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI), a 5-HT2A receptor agonist, altered timing precision and accuracy in mice performing the discrete-trials temporal discrimination task (TDT), a retrospective timing task where subjects differentially respond depending on...

Partial rescue of schizophrenia-related phenotypes in young adult Sp4 hypomorphic mice.

Journal of Psychiatric Research July 1, 2025 Joris Kamp, Megan E Sikkink, Mahalah R Buell et al.

The Schizophrenia Exome Sequencing Meta-Analysis (SCHEMA) Consortium found that truncation of one copy of the SP4 gene has an odds ratio of 9.37 (3.38-29.7) for schizophrenia (SCZ). Human SP4 gene is also one of the 69 schizophrenia-risk genes prioritized by parallel genome-wide association studies (GWAS) and one of the two schizophrenia-risk genes shared between the SCHEMA and the GWAS,...

Acute serotonin 2A receptor activation impairs behavioral flexibility in mice.

Behavioural Brain Research October 1, 2020 Dionisio A Amodeo, Omron Hassan, Landon M. Klein et al. 25 citations

Serotonin 2A (5-HT2A) receptors are the primary site of action of hallucinogenic drugs and the target of atypical antipsychotics. 5-HT2A receptors are also implicated in executive function, including behavioral flexibility. Previous studies showed that 5-HT2A receptor blockade improved behavioral flexibility in rodent models related to autism spectrum disorder and schizophrenia. The current...

DOI: 10.1016/j.bbr.2020.112861 (opens in new tab) Full text (opens in new tab) Serotonin 5-ht2a Behavioral flexibility Probabilistic reversal learning

Phencyclidine increased while isolation rearing did not affect progressive ratio responding in rats: Investigating potential models of amotivation in schizophrenia.

Behavioural Brain Research May 17, 2019 Nurith Amitai, Susan B Powell, Jared W Young

Schizophrenia is a debilitating neurodevelopmental disorder affecting 1% of the global population with heterogeneous symptoms including positive, negative, and cognitive. While treatment for positive symptoms exists, none have been developed to treat negative symptoms. Animal models of schizophrenia are required to test targeted treatments and since patients exhibit reduced effort (breakpoints)...

Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen

Psychopharmacology February 14, 2019 Adam L. Halberstadt, Jochem V. F. Zee, Muhammad Chatha et al. 21 citations

Background There is evidence that mGlu2/3 receptors regulate 5-HT_2A signaling, interactions that have been theorized to play a role in the antipsychotic-like effects of mGlu2/3 agonists as well as the hallucinogenic effects of 5-HT_2A agonists. One approach to unraveling this interaction is through the chronic administration of agonists at the two receptors, which should influence the...

Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice.

Pharmacology, Biochemistry, and Behavior September 1, 2016 Adam L. Halberstadt, James Hyun, Michael A Ruderman et al.

N-allylnormetazocine (NANM; SKF 10,047) is a benzomorphan opioid that produces psychotomimetic effects. (+)-NANM is the prototypical agonist for the sigma-1 (σ1) receptor, and there is a widespread belief that the hallucinogenic effects of NANM and other benzomorphan derivatives are mediated by interactions with σ1 sites. However, NANM is also an agonist at the κ opioid receptor (KOR) and binds...

DOI: 10.1016/j.pbb.2016.05.009 (opens in new tab) Full text (opens in new tab) Dissociative Hallucinogen Kappa receptor Mice +3

The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents.

Psychopharmacology April 1, 2016 Adam L. Halberstadt, Natalia Slepak, James Hyun et al.

Methoxetamine (MXE) is a ketamine analog sold online that has been subject to widespread abuse for its dissociative and hallucinogenic effects. Previous studies have shown that MXE has high affinity for the phencyclidine (PCP) binding site located within the channel pore of the NMDA receptor (NMDAR), but little is known about its behavioral effects. Dissociative anesthetics such as ketamine and...

DOI: 10.1007/s00213-016-4203-3 (opens in new tab) Full text (opens in new tab) Behavioral pattern monitor Ketamine isomers Locomotor activity Methoxetamine +3

Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.

Neuropharmacology July 2013 Adam L. Halberstadt, Susan B Powell, Mark A. Geyer

The 5-HT₂A receptor mediates the effects of serotonergic hallucinogens and may play a role in the pathophysiology of certain psychiatric disorders, including schizophrenia. Given these findings, there is a need for animal models to assess the behavioral effects of 5-HT₂A receptor activation. Our previous studies demonstrated that the phenylalkylamine hallucinogen and 5-HT₂A/₂C agonist...

Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice

Psychopharmacology December 9, 2010 Adam L. Halberstadt, Virginia Lehmann-Masten, Mark A. Geyer et al. 35 citations

RATIONALE: Metabotropic glutamate (mGlu) receptors have been suggested to play a role in neuropsychiatric disorders including schizophrenia, drug abuse, and depression. Because serotonergic hallucinogens increase glutamate release and mGlu receptors modulate the response to serotonin (5-HT)(2A) activation, the interactions between serotonin 5-HT(2A) receptors and mGlu receptors may prove to be...

Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice

Journal of Psychopharmacology December 8, 2010 Liselore Koedood, Adam L. Halberstadt, Susan B Powell et al. 212 citations

Psilocin (4-hydroxy- N, N-dimethyltryptamine) is a hallucinogen that acts as an agonist at 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors. Psilocin is the active metabolite of psilocybin, a hallucinogen that is currently being investigated clinically as a potential therapeutic agent. In the present investigation, we used a combination of genetic and pharmacological approaches to identify the...

A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice

Journal of young investigators July 1, 2009 Michael A Ruderman, Susan B Powell, Mark A. Geyer

Sensorimortor gating and locomotion are behaviors that reflect pre-attentive sensory filtering and higher order, top-down, sensory processing, respectively. These processes are thought to affect either the perception of novelty in an environment (filtering) or cognition (higher order processing), salient features of models of altered states of consciousness (ASC). Drugs with highly selective...

5-HT_2A and 5-HT_2C Receptors Exert Opposing Effects on Locomotor Activity in Mice

Neuropsychopharmacology July 1, 2009 Adam L. Halberstadt, Iris Van der Heijden, Michael A Ruderman et al.

Although it is well established that hallucinogens act as 5-HT_2A and 5-HT_2C receptor agonists, little is known about the relative contributions of 5-HT_2A and 5-HT_2C receptors to the acute behavioral effects of these drugs. The behavioral pattern monitor was used to characterize the effects of the hallucinogen 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on locomotor and investigatory...